Marvelon treatment of menopausal transition dysfunctional uterine bleeding observed.docVIP

 PAGE \* MERGEFORMAT 6 Marvelon treatment of menopausal transition dysfunctional uterine bleeding observed [Keywords:] Marvelon treatment of menopausal transition uterine bleeding observed Collected in our hospital gynecology clinic in January 2007 to May 2008 the treatment of patients with menopausal transition in 65 cases of dysfunctional uterine bleeding, application Marvelon treatment achieved good results, are reported below. 1 Data and methods 1.1 General Information 65 patients aged 40 to 49 years, mean age 43.5 years, were irregular uterine bleeding symptoms, history of 3 months to 1 years, and general medicine and non-steroidal anti-inflammatory drugs symptomatic treatment fails, the Blood Circulation conventional, coagulation, liver and kidney function, thyroid function range, urine pregnancy test and pelvic ultrasound examination ruled out the blood system, pregnancy-related, reproductive system cancer and thyroid, liver and other diseases, the line of hysteroscopic curettage and postoperative return of endometrial pathology in 41 cases of simple hyperplasia, complex hyperplasia in 24 cases, 65 patients curettage 3 months ago there was no history of hormone therapy drugs. 1.2 Methods In the first 5 days after curettage started Marvelon oral, 1 day, each one, and even served 21 days for a period of withdrawal bleeding after stopping 1 day 2 cycles of therapy, were treated with 3 cycles , monitoring of liver function before and after treatment, the three sex hormones (E2, FSH, LH) and endometrial thickness. 1.3 Statistical analysis Using 2 test. 2 Results 2.1 Clinical results The group of 64 patients withdrew treatment of vaginal blood loss bleeding drug was gradually decreasing trend, and 1 patient due to vaginal bleeding 1 cycle is still diverted to other treatments, were followed up 3 months after treatment, 62 patients with menstrual regularity, 2 patients with amenorrhea. 2.2 The change of serum sex hormone l